3-(trifluoromethanesulfonyloxy)-6-(piperidin-1-yl)xanthen-9-one | 1079889-35-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 3-(trifluoromethanesulfonyloxy)-6-(piperidin-1-yl)xanthen-9-one
• 英文别名: 3-(Trifluoromethanesulfonyloxy)-6-(piperidin-1-yl)-xanthen-9-one；(9-oxo-6-piperidin-1-ylxanthen-3-yl) trifluoromethanesulfonate
• CAS: 1079889-35-2
• 化学式: C₁₉H₁₆F₃NO₅S
• 分子量: 427.401
• InChiKey: ZJTJQLXYRJMSNK-UHFFFAOYSA-N

物化性质

• 沸点：
  588.3±50.0 °C(Predicted)
• 密度：
  1.487±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  29
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  81.3
• 氢给体数：
  0
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  3-(trifluoromethanesulfonyloxy)-6-(piperidin-1-yl)xanthen-9-one 在 正丁基锂 、 palladium diacetate 、 caesium carbonate 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 33.08h， 生成
  参考文献：
  名称：

  Efficient synthesis of fluorescent rosamines: multifunctional platforms for cellular imaging

  摘要：

  Substituted rosamines are efficiently prepared through a new organometallic addition to an iminesubstituted xanthone as a novel primary amine equivalent. The synthesis reduces the number of synthetic steps to the targeted rosamines, for convenient and facile access to potential libraries of rosamine dyes. The prepared rosamine derivatives represent unique multifunctional platforms that possess radiolabeling capability and fluorescence. Rosamines have (i) useful non-specific binding properties in mammalian cells and plant root hair, and (ii) positive uptake or binding properties in microbial systems. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2014.01.067
• 作为产物：
  描述：

  哌啶 、 9-oxo-9H-xanthene-3,6-diyl bis(trifluoromethanesulfonate) 在 水 、 EtOAc Hexanes 作用下， 以 二甲基亚砜 、 二氯甲烷 为溶剂， 反应 1.5h， 以to afford the pure product (372 mg, 87%) as a light yellow solid的产率得到3-(trifluoromethanesulfonyloxy)-6-(piperidin-1-yl)xanthen-9-one
  参考文献：
  名称：

  ROSAMINE DERIVATIVES AS AGENTS FOR THE TREATMENT OF CANCER

  摘要：

  本发明涉及一类新的罗萨明衍生物，其中在一种实施例中，化合物具有结构式（I）或其任何药学上可接受的盐或溶剂，其中：R1代表芳基，Het1或C1-6烷基，后一群基团可以被芳基或Het2取代；R2a和R2b共同形成C3.8n-烷基，该烷基可以被来自卤素，C1-4烷基，C（O）OH和C（O）O-C1-4烷基中的一个或多个取代基取代，并且该烷基可以被X1中断；R3a和R3b共同形成C3-6 / 7-烷基，该烷基可以被来自卤素，C1-4烷基，C（O）OH和C（O）O-C1-4烷基中的一个或多个取代基取代，并且该烷基可以被X2中断；X1和X2独立地表示O，S或NR4；R4在每次出现时独立地表示H，C（O）OR5，C（O）R6a，C（O）N（R6b）R6c或C1-6烷基，后一群基团可以被一个或多个来自卤素，芳基和Het3的取代基所取代，或被一个单独的C（O）OR1a基团所取代；R4a表示H或C1-4烷基；R5表示芳基，Het4或C1-6烷基，后一群基团可以被一个或多个来自卤素，芳基和Het5的取代基所取代；R5到R6d独立地表示H或R5；每个芳基独立地表示C6-10碳环芳基，该芳基可以包含一个或两个环，并且可以被一个或多个来自卤素，CN，C1-6烷基（后一群基团可以被一个或多个来自卤素，OR7，苯基，萘基和Het6的取代基所取代）和OR8的取代基所取代；R7和R8独立地表示H，C1-4烷基（可以被一个或多个卤素或单个苯基或C（O）OR8取代基所取代），Het7，苯基或萘基；R8a表示H或C1-4烷基；Het1到Het7独立地表示含有一个或多个来自氧，氮和/或硫的杂原子的5-至10元芳香，完全饱和或部分不饱和的杂环族群，该杂环族群可以包含一个或两个环，并且可以被一个或多个来自卤素，CN，C1-6烷基（后一群基团可以被一个或多个来自卤素，OR9和苯基的取代基所取代）和OR10的取代基所取代；R9和R10独立地表示H，C1-4烷基或苯基；除非另有说明，否则烷基可以被一个或多个卤素原子取代；A'表示药学上可接受的阴离子。还公开了制备和使用化合物以及制药组合物的方法。

  公开号：

  US20110212955A1

文献信息

• [EN] ROSAMINE DERIVATIVES AS AGENTS FOR THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS DE ROSAMINE COMME AGENTS POUR LE TRAITEMENT D'UN CANCER
  申请人：CANCER RES INITIATIVES FOUNDAT

  公开号：WO2010033011A1

  公开（公告）日：2010-03-25

  The present invention relates to a new class of rosamine derivatives, in one embodiment, the compounds have the structure (I) or any pharmaceutically acceptable salt or solvate thereof, wherein: R1 represents aryl, Het1 or C1-6 alkyl, which latter group is optionally substituted by aryl or Het2; R2a and R2b together form C3.8n-alkylene, which alkylene group is optionally substituted by one or more substituents selected from halo, C1-4 alkyl, C(O)OH and C(O)O-C1-4, alkyl.and which alkylene group is optionally interrupted by X1; R3a and R3b together form C3-6 /7-alkylene, which alkylene group is optionally substituted by one or more substituents selected from halo, C1-4 alkyl, C(O)OH and C(O)O-C1-4 alkyl, and which alkylene group is optionally interrupted by X2; X1 and X2 independently represent O, S, or NR4; R4 represents, independently at each occurrence, H, C(O)OR5, C(0)R6a, C(O)N(R6b)R6c or C1-6, alkyl, which latter group is optionally substituted by one or more substituents selected from halo, aryl and Het3 or is substituted by a single C(0)0R1a group; R4a represents H or C1-4 alkyl; R5 represents aryl, Het4 or C1-6 alkyl optionally substituted by one or more substituents selected from halo, aryl and Het5; R5e to R6d independently represent H or R5; each aryl independently represents a C6-10 carbocyclic aromatic group, which group may comprise either one or two rings and may be substituted by one or more substituents selected from halo, CN, C1-6 alkyl (which latter group is optionally substituted by one or more substituents selected from halo, OR7, phenyl, naphthyl and Het6) and OR8; R7 and R8 independently represent H, C1-4 alkyl (optionally substituted by one or more halo groups or by a single phenyl or C(O)OR8a substituent), Het7, phenyl or naphthyl; R8a represents H or C1-4 alkyl; Het1 to Het7 independently represent 5- to 10-membered aromatic, fully saturated or partially unsaturated heterocyclic groups containing one or.more heteroatoms selected from oxygen, nitrogen and/or sulfur, which heterocyclic groups may comprise one or two rings and may be substituted by one or more substituents selected from Halo, CN, C1-6 alkyl (which latter group is optionally substituted by one or more substituents selected from halo, OR9 and phenyl) and OR10; R9 and R10 independently represent H, C1-4 alkyl or phenyl; unless otherwise specified, alkyl groups are optionally substituted by one or more halo atoms; and A' represents a pharmaceutically acceptable anion. Also disclosed are methods for making and using ' compounds as well as pharmaceutical compositions.

  本发明涉及一类新的罗萨明衍生物，其中在一个实施例中，化合物具有结构（I）或其任何药学上可接受的盐或溶剂，其中：R1代表芳基、Het1或C1-6烷基，后者可由芳基或Het2取代；R2a和R2b一起形成C3.8n-烷基，该烷基可由卤素、C1-4烷基、C(O)OH和C(O)O-C1-4烷基中选择的一个或多个取代基取代，并且该烷基可由X1中断；R3a和R3b一起形成C3-6/7-烷基，该烷基可由卤素、C1-4烷基、C(O)OH和C(O)O-C1-4烷基中选择的一个或多个取代基取代，并且该烷基可由X2中断；X1和X2独立地表示O、S或NR4；R4在每次出现时独立地表示H、C(O)OR5、C(0)R6a、C(O)N(R6b)R6c或C1-6烷基，后者可由卤素、芳基和Het3中选择的一个或多个取代基取代，或者由单个C(0)0R1a基团取代；R4a表示H或C1-4烷基；R5代表芳基、Het4或C1-6烷基，可由卤素、芳基和Het5中选择的一个或多个取代基取代；R5e到R6d独立地表示H或R5；每个芳基独立地表示一个含有6-10个碳环芳族的芳基，该芳基可能包含一个或两个环，并且可能被一个或多个取代基如卤素、CN、C1-6烷基（后者可由一个或多个取代基如卤素、OR7、苯基、萘基和Het6取代）和OR8取代；R7和R8独立地表示H、C1-4烷基（可由一个或多个卤素基或单个苯基或C(O)OR8a取代基取代）、Het7、苯基或萘基；R8a表示H或C1-4烷基；Het1到Het7独立地表示含有一个或多个异氧、氮和/或硫的芳族、完全饱和或部分不饱和的杂环基，这些杂环基可能包含一个或两个环，并且可能被一个或多个取代基如卤素、CN、C1-6烷基（后者可由一个或多个取代基如卤素、OR9和苯基取代）和OR10取代；R9和R10独立地表示H、C1-4烷基或苯基；除非另有规定，烷基可能由一个或多个卤素原子取代；A'表示药学上可接受的阴离子。还公开了制备和使用该化合物以及制药组合物的方法。
• 소광자 및 이의 용도
  申请人：SFC CO., LTD. 에스에프씨 주식회사(120060087061) Corp. No ▼ 135511-0105889BRN ▼134-81-54429

  公开号：KR20190062162A

  公开（公告）日：2019-06-05

  본 발명은 들뜬 에너지 준위에서 발광 특성을 나타내는 형광 물질에 대한 소광 효과를 나타내는 소광자와 이의 다양한 용도에 관한 것이다.

  这项发明涉及荧光物质，它在激发能级下表现出发光特性的荧光物质，并涉及显示其发光效果的荧光体以及其各种用途。
• ROSAMINE DERIVATIVES AS AGENTS FOR THE TREATMENT OF CANCER
  申请人：Lee Hong Boon

  公开号：US20110212955A1

  公开（公告）日：2011-09-01

  The present invention relates to a new class of rosamine derivatives, in one embodiment, the compounds have the structure (I) or any pharmaceutically acceptable salt or solvate thereof, wherein: R 1 represents aryl, Het 1 or C 1-6 alkyl, which latter group is optionally substituted by aryl or Het 2 ; R 2a and R 2b together form C 3.8 n-alkylene, which alkylene group is optionally substituted by one or more substituents selected from halo, C 1-4 alkyl, C(O)OH and C(O)O—C 1-4 , alkyl and which alkylene group is optionally interrupted by X 1 ; R 3a and R 3b together form C 3-6 /7-alkylene, which alkylene group is optionally substituted by one or more substituents selected from halo. C 1-4 alkyl, C(O)OH and C(O)O—C 1-4 alkyl, and which alkylene group is optionally interrupted by X 2 ; X 1 and X 2 independently represent O, S, or NR 4 ; R 4 represents, independently at each occurrence, H, C(O)OR 5 , C(O)R 6a , C(O)N(R 6b )R 6c or C 1-6 , alkyl, which latter group is optionally substituted by one or more substituents selected from halo, aryl and Het 3 or is substituted by a single C(O)OR 1a group; R 4a represents H or C 1-4 alkyl; R 5 represents aryl, Het 4 or C 1-6 alkyl optionally substituted by one or more substituents selected from halo, aryl and Het 5 ; R 5e to R 6d independently represent H or R 5 ; each aryl independently represents a C 6-10 carbocylic aromatic group, which group may comprise either one or two rings and may be substituted by one or more substituents selected from halo, CN, C 1-6 alkyl (which latter group is optionally substituted by one or more substituents selected from halo, OR 7 , phenyl, napthyl and Het 6 ) and OR 8 ; R 7 and R 8 independently represent H, C 1-4 alkyl (optionally substituted by one or more halo groups or by a single phenyl or C(O)OR 8a substituent), Het 7 , phenyl or naphthyl; R 8a represents H or C 1-4 alkyl; Het 1 to Het 7 independently represent 5- to 10-membered aromatic, fully saturated or partially unsaturated heterocyclic groups containing one or more heteroatoms selected from oxygen, nitrogen and/or sulphur, which heterocyclic groups may comprise one or two rings and may be substituted by one or more substituents selected from Halo, CN, C 1-6 alkyl (which latter group is optionally substituted by one or more substituents selected from halo, OR 9 and phenyl) and OR 10 ; R 9 and R 10 independently represent H, C 1-4 alkyl or phenyl; unless otherwise specified, alkyl groups are optionally substituted by one or more halo atoms; and A′ represents a pharmaceutically acceptable anion. Also disclosed are methods for making and using compounds as well as pharmaceutical compositions.

  本发明涉及一类新的罗萨明衍生物，其中在一种实施例中，化合物具有结构式（I）或其任何药学上可接受的盐或溶剂，其中：R1代表芳基，Het1或C1-6烷基，后一群基团可以被芳基或Het2取代；R2a和R2b共同形成C3.8n-烷基，该烷基可以被来自卤素，C1-4烷基，C（O）OH和C（O）O-C1-4烷基中的一个或多个取代基取代，并且该烷基可以被X1中断；R3a和R3b共同形成C3-6 / 7-烷基，该烷基可以被来自卤素，C1-4烷基，C（O）OH和C（O）O-C1-4烷基中的一个或多个取代基取代，并且该烷基可以被X2中断；X1和X2独立地表示O，S或NR4；R4在每次出现时独立地表示H，C（O）OR5，C（O）R6a，C（O）N（R6b）R6c或C1-6烷基，后一群基团可以被一个或多个来自卤素，芳基和Het3的取代基所取代，或被一个单独的C（O）OR1a基团所取代；R4a表示H或C1-4烷基；R5表示芳基，Het4或C1-6烷基，后一群基团可以被一个或多个来自卤素，芳基和Het5的取代基所取代；R5到R6d独立地表示H或R5；每个芳基独立地表示C6-10碳环芳基，该芳基可以包含一个或两个环，并且可以被一个或多个来自卤素，CN，C1-6烷基（后一群基团可以被一个或多个来自卤素，OR7，苯基，萘基和Het6的取代基所取代）和OR8的取代基所取代；R7和R8独立地表示H，C1-4烷基（可以被一个或多个卤素或单个苯基或C（O）OR8取代基所取代），Het7，苯基或萘基；R8a表示H或C1-4烷基；Het1到Het7独立地表示含有一个或多个来自氧，氮和/或硫的杂原子的5-至10元芳香，完全饱和或部分不饱和的杂环族群，该杂环族群可以包含一个或两个环，并且可以被一个或多个来自卤素，CN，C1-6烷基（后一群基团可以被一个或多个来自卤素，OR9和苯基的取代基所取代）和OR10的取代基所取代；R9和R10独立地表示H，C1-4烷基或苯基；除非另有说明，否则烷基可以被一个或多个卤素原子取代；A'表示药学上可接受的阴离子。还公开了制备和使用化合物以及制药组合物的方法。
• Efficient synthesis of fluorescent rosamines: multifunctional platforms for cellular imaging
  作者：George A. Kraus、Tezcan Guney、Aaron Kempema、Joel M. Hyman、Bahram Parvin

  DOI：10.1016/j.tetlet.2014.01.067

  日期：2014.2

  Substituted rosamines are efficiently prepared through a new organometallic addition to an iminesubstituted xanthone as a novel primary amine equivalent. The synthesis reduces the number of synthetic steps to the targeted rosamines, for convenient and facile access to potential libraries of rosamine dyes. The prepared rosamine derivatives represent unique multifunctional platforms that possess radiolabeling capability and fluorescence. Rosamines have (i) useful non-specific binding properties in mammalian cells and plant root hair, and (ii) positive uptake or binding properties in microbial systems. (C) 2014 Elsevier Ltd. All rights reserved.